Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
156 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Autism - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Autism - Pipeline Review, H2 2014', provides an overview of the Autism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Autism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Autism Overview 10 Therapeutics Development 11 Pipeline Products for Autism - Overview 11 Pipeline Products for Autism - Comparative Analysis 12 Autism - Therapeutics under Development by Companies 13 Autism - Therapeutics under Investigation by Universities/Institutes 16 Autism - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Autism - Products under Development by Companies 21 Autism - Products under Investigation by Universities/Institutes 22 Autism - Companies Involved in Therapeutics Development 23 F. Hoffmann-La Roche Ltd. 23 Sumitomo Dainippon Pharma Co., Ltd. 24 Egenix, Inc. 25 Novartis AG 26 Merz Pharma GmbH & Co. KgaA 27 Mitsubishi Tanabe Pharma Corporation 28 Teva Pharmaceutical Industries Limited 29 BrainStorm Cell Therapeutics Inc. 30 Avanir Pharmaceuticals, Inc. 31 Curemark, LLC 32 Coronado Biosciences, Inc. 33 Omeros Corporation 34 Intra-Cellular Therapies, Inc. 35 Cellceutix Corporation 36 Heptares Therapeutics Ltd. 37 Edison Pharmaceuticals, Inc. 38 Otsuka Holdings Co., Ltd. 39 Reviva Pharmaceuticals Inc. 40 Naurex, Inc. 41 Mnemosyne Pharmaceuticals, Inc. 42 BioCrea GmbH 43 Saniona AB 44 Confluence Pharmaceuticals LLC 45 MedDay 46 Autism - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Combination Products 48 Assessment by Target 49 Assessment by Mechanism of Action 52 Assessment by Route of Administration 55 Assessment by Molecule Type 57 Drug Profiles 59 CM-AT - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 lurasidone hydrochloride - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 aripiprazole - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 fluoxetine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 memantine hydrochloride - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 CNDO-201 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 (dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 oxytocin - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 vatiquinone - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 RG-7314 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 fluoxetine - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 fingolimod hydrochloride - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Stem Cell Therapy for Autism - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 glatiramer acetate - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 ITI-007 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Stem Cell Therapy for Central Nervous System Disorders, Genetic Disorders and Musculoskeletal Disorders - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 KM-391 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecule to Antagonize mGluR5 for Autism, Depression and Dyskinesia - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 CN-2097 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Small Molecule to Target GPR63 for Autism - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 acamprosate calcium - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 suramin hexasodium - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 carbetocin - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Small Molecule to Modulate GABRA5 Receptor for Alzheimer's Disease, Schizophrenia and Autism - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Drug for Autism - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 NRX-20xx - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Drug to Agonize GABA Alpha 4 Delta Receptor for Autism and Sleep Disorders - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 Drugs for Autism - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Small Molecules for Cancer and Autism - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 Drug for Autism Spectrum Disorders - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 Small Molecules to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 RP-5063 - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 oxytocin - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 MD-1103 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 Autism - Recent Pipeline Updates 116 Autism - Dormant Projects 147 Autism - Discontinued Products 148 Autism - Product Development Milestones 149 Featured News & Press Releases 149 Jun 26, 2014: Coronado Biosciences Reports Topline Results from Investigator Initiated Pilot Study of TSO in Adults with Autism Spectrum Disorder 149 May 14, 2014: Coronado Biosciences Initiates Phase 2a Clinical Study of TSO in Pediatric Patients With Autism Spectrum Disorder 149 Feb 14, 2014: New funding puts Rett Syndrome cure on the horizon 149 Dec 12, 2013: Coronado Biosciences Announces Presentation of Interim Data From Autism Study at Neuropsychopharmacology Meeting 150 Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment 151 Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 151 Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 152 Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 152 Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism 152 Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model 153 Appendix 155 Methodology 155 Coverage 155 Secondary Research 155 Primary Research 155 Expert Panel Validation 155 Contact Us 156 Disclaimer 15
List of Tables Number of Products under Development for Autism, H2 2014 11 Number of Products under Development for Autism - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 14 Number of Products under Development by Companies, H2 2014 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2014 16 Comparative Analysis by Late Stage Development, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Comparative Analysis by Unknown Stage Development, H2 2014 20 Products under Development by Companies, H2 2014 21 Products under Investigation by Universities/Institutes, H2 2014 22 Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 23 Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 24 Autism - Pipeline by Egenix, Inc., H2 2014 25 Autism - Pipeline by Novartis AG, H2 2014 26 Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014 27 Autism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 28 Autism - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 29 Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2014 30 Autism - Pipeline by Avanir Pharmaceuticals, Inc., H2 2014 31 Autism - Pipeline by Curemark, LLC, H2 2014 32 Autism - Pipeline by Coronado Biosciences, Inc., H2 2014 33 Autism - Pipeline by Omeros Corporation, H2 2014 34 Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 35 Autism - Pipeline by Cellceutix Corporation, H2 2014 36 Autism - Pipeline by Heptares Therapeutics Ltd., H2 2014 37 Autism - Pipeline by Edison Pharmaceuticals, Inc., H2 2014 38 Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 39 Autism - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 40 Autism - Pipeline by Naurex, Inc., H2 2014 41 Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 42 Autism - Pipeline by BioCrea GmbH, H2 2014 43 Autism - Pipeline by Saniona AB, H2 2014 44 Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2014 45 Autism - Pipeline by MedDay, H2 2014 46 Assessment by Monotherapy Products, H2 2014 47 Assessment by Combination Products, H2 2014 48 Number of Products by Stage and Target, H2 2014 51 Number of Products by Stage and Mechanism of Action, H2 2014 54 Number of Products by Stage and Route of Administration, H2 2014 56 Number of Products by Stage and Molecule Type, H2 2014 58 Autism Therapeutics - Recent Pipeline Updates, H2 2014 116 Autism - Dormant Projects, H2 2014 147 Autism - Discontinued Products, H2 2014 148
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
